Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases

Table 1 Hepatocellular carcinoma mortality by patient’s characteristics n (%)

		Yes	No	Total	P value
Gender	Men	120 (67.8)	57 (32.2)	177	0.24
	Women	52 (74.3)	18 (25.7)	70
Age (yr)	≤ 65	39 (61.9)	24 (38.1)	63	0.17
	> 65	133 (72.3)	51 (27.7)	184
Calendar period	2000-2005	116 (92.1)	10 (7.9)	126	< 0.01
	2006-2010	56 (46.3)	65 (53.7)	121
Etiology	Viral infection	108 (69.7)	47 (30.3)	155	< 0.01
	Alcohol	38 (80.9)	9 (19.1)	47
	Other	25 (56.8)	19 (43.2)	44
BCLC stage	A	59 (56.7)	45 (43.3)	104	< 0.01
	B	79 (74.5)	27 (25.5)	106
	C-D	34 (91.9)	3 (8.1)	37
Treatment	No	60 (93.8)	4 (6.3)	64	0.04
	Yes	112 (61.2)	71 (38.8)	183
Surveillance	No	134 (72.0)	52 (28.0)	186	0.20
	Yes	38 (62.3)	23 (37.7)	61
Alpha-fetoprotein	Normal	104 (59.8)	70 (40.2)	174	< 0.01
	Elevated (> 15)	43 (91.5)	4 (8.5)	47
Bilirubin	Normal	48 (57.8)	35 (42.2)	83	< 0.01
	Elevated (> 2.1)	98 (77.8)	28 (22.2)	126

BCLC: Barcelona Clinic Liver Cancer.

Table 2 Predictors of hepatocellular carcinoma mortality

	Multivariate analysis-Cox proportional hazards model
		HR	95%CI
Gender	Men	1
	Women	1.22	0.86-1.72
Age (yr)	≤ 65	1
	> 65	1.20	0.82-1.75
Calendar period	2000-2005	1
	2006-2010	0.67	0.46-0.95
Etiology	Viral infection	1
	Alcohol	1.43	0.96-2.12
	Other	0.95	0.59-1.53
BCLC stage	A	1
	B	1.50	1.03-2.19
	C-D	1.75	1.01-3.03
Treatment	No	1
	Yes	0.37	0.24-0.57
Surveillance	No	1
	Yes	1.10	0.74-1.65

BCLC: Barcelona Clinic Liver Cancer.